

# UNIVERSITY OF BIRMINGHAM

University of Birmingham  
Research at Birmingham

## Patterns of patient withdrawal from BCG treatment for bladder cancer

Alcorn, Jason; Burton, Rob; Topping, Annie

DOI:

[10.1111/ijun.12191](https://doi.org/10.1111/ijun.12191)

### Document Version

Peer reviewed version

### Citation for published version (Harvard):

Alcorn, J, Burton, R & Topping, A 2019, 'Patterns of patient withdrawal from BCG treatment for bladder cancer: a retrospective time interval analysis', *International Journal of Urological Nursing*, vol. 13, no. 2, pp. 63-74. <https://doi.org/10.1111/ijun.12191>

[Link to publication on Research at Birmingham portal](#)

### Publisher Rights Statement:

This is the peer reviewed version of the following article: Alcorn, J, Burton, R, Topping, A. Patterns of patient withdrawal from BCG treatment for bladder cancer: A retrospective time interval analysis. *Int J Urol Nurs*. 2019; 1– 12. <https://doi.org/10.1111/ijun.12191>, which has been published in final form at <https://doi.org/10.1111/ijun.12191>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.



**PATTERNS OF PATIENT WITHDRAWAL FROM BCG  
TREATMENT FOR BLADDER CANCER: A RETROSPECTIVE  
TIME INTERVAL ANALYSIS**

Journal:	<i>International Journal of Urological Nursing</i>
Manuscript ID	IJUN-2019-0374.R1
Manuscript Type:	Original Research Article
Keywords:	Bladder Cancer, Non-muscle invasive bladder cancer, Urothelial cancer, Bacillus Calmette-Guerin, BCG, Intravesical treatment, Early withdrawal

SCHOLARONE™  
Manuscripts

# PATTERNS OF PATIENT WITHDRAWAL FROM BCG TREATMENT FOR BLADDER CANCER: A RETROSPECTIVE TIME INTERVAL ANALYSIS

## ABSTRACT

### Research Aims

What were the patterns that have been recorded for withdrawal from treatment?

What individual factors influenced withdrawal from BCG treatment?

### Literature Review

Bacillus Calmette-Guerin (BCG) vaccine was first introduced at the turn of the 19-20th century and since the 1970s has become significant in the treatment of non-muscle invasive bladder cancer (NMIBC). It is concerning to note that little is known about the patient experience of this intravesical treatment, which is particularly concerning. Despite over 50 years of clinical use, early withdrawal from treatment rates of between 32% - 86% have been reported in the literature. This study sought to estimate the rate of non-completion of BCG regime in one English National Health Service Cancer Unit and identify factors that contributed to patients' decisions to withdraw.

### Methodology

A retrospective observational time interval study of a consecutive sample 234 case records of patients who underwent intravesical BCG treatment in one English National Health Service Cancer Unit, using time to event analysis. The population for this review was from a large metropolitan area in England, including a large northern town and satellites where heavy industry had dominated.

### Results

The overall withdrawal rate was 211 (90%) prior to completion of induction and maintenance regime. The majority, 107 (46%) withdrew-from treatment within the first

1  
2  
3 year. Age, number of side effects and symptoms, and contact with CNS were all  
4  
5 associated with withdrawal.  
6

### 7 8 **Conclusions**

9  
10 The data has shown that age, side effects, contact details and information giving may  
11  
12 be factors that contribute to a patient deciding whether they stay on treatment or  
13  
14 withdraw from it.  
15

### 16 17 **Funding / Competing interests**

18  
19 None to declare  
20

### 21 22 **Keywords**

23  
24 Bladder cancer, Non-muscle invasive bladder cancer, Urothelial cancer, Bacillus  
25  
26 Calmette-Guerin, BCG, Intravesical treatment, Early withdrawal  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1. Introduction

In 2015, there were over 10,000 new cases of bladder cancer recorded in the UK only

<sup>1</sup>. This accounts for 3% of all new cancer cases, with males being three times more likely to develop the disease than females. It is highest in people aged 85-89 years. The incidence rates for bladder cancer have been seen to be falling since the early 1990's. Reasons offered for this decline include reductions in tobacco smoking or exposure to occupational carcinogens, particularly amongst men <sup>2</sup>. There has also been a shift from industrial to predominantly service occupations in the UK <sup>3</sup>. Although tobacco smoking is still associated with around 50% of bladder cancers <sup>4-7</sup> and more prevalent amongst people living in deprived areas <sup>1</sup>.

Transitional cell bladder cancer or urothelial cancer accounts for approximately 90% of all bladder cancers in the UK <sup>1</sup>. Non-muscle invasive, superficial or early, bladder cancer is characterised by abnormal cells localised to the lining of the bladder. Apart from recommended lifestyle changes such as smoking cessation, following a transurethral resection of bladder tumour (TURBT) intravesical treatment with Bacillus Calmette-Guerin (BCG) is considered the gold standard for preventing recurrence and disease progression in non-muscle invasive bladder cancer (NMIBC) <sup>8</sup>. Intravesical treatment involves instilling BCG into the bladder via a catheter. A proportion of patients, in some studies as high as 86%, fail to complete treatment <sup>9</sup>. This low level of concordance could have consequences in terms of disease progression and ultimately need for radical surgical interventions.

At the turn of the 19 - 20<sup>th</sup> century Albert Calmette and Camille Guerin isolated an attenuated live strain of Mycobacterium bovis bacillus, a live vaccine against

1  
2  
3 tuberculosis, known as BCG<sup>10,11</sup>. During a series of post mortems in 1929, Pearl noted  
4 a lower incidence of bladder cancer in patients with tuberculosis<sup>12</sup>. Subsequent  
5 laboratory studies demonstrated the anti-tumour effects of BCG against several  
6 malignant cell lines<sup>13–16</sup>. In the late seventies Morales et al. (1976) undertook a  
7 preliminary study evaluating the effects of BCG treatment on nine patients with  
8 NMIBC. Study participants were treated with intravesical BCG once a week for six-  
9 weeks, achieving a complete response rate in 7 (78%) of patients<sup>17</sup>. The effectiveness  
10 of this regime was later replicated in both the American South Western Oncology  
11 Group (SWOG) and the Memorial Sloan-Kettering Hospital in larger well designed  
12 control trials<sup>18–21</sup>.

22  
23  
24  
25  
26  
27  
28  
29 Several well designed randomised clinical trials have since compared TURBT as a  
30 single treatment, against a TURBT followed by BCG<sup>18,22–24</sup>. Other randomised trials  
31 and meta-analyses compared various combinations of TURBT, chemotherapy and  
32 BCG regimes<sup>9,25–30</sup>. These studies demonstrated significant reductions in NMIBC  
33 recurrence rates of up to 57% in patients treated with BCG, compared to rates of up  
34 to 32% when treated with TURBT alone, or with chemotherapy.

35  
36  
37  
38  
39  
40  
41  
42  
43  
44 Globally sub strains of BCG such as Pasteur, TICE, Armand-Frappier, Glaxo,  
45 Connaught and others are in use<sup>31</sup> creating an absence of clarity regarding optimum  
46 strain or dose, as well as different regimes and doses<sup>30–32</sup>. A consensus statement  
47 concluded that regimens other than SWOG have not shown the same reliability<sup>33</sup>.  
48 Only one study compared two strains head to head<sup>34</sup>. They compared the Connaught  
49 and TICE strains and showed a statistically significant difference ( $p < 0.002$ ) in five-year  
50 recurrence-free survival for Connaught (75%) over TICE (46%) treated patients.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 At present there remains no overwhelming evidence indicating the optimal efficacy for  
7  
8 the most appropriate induction and maintenance regime. This is illustrated in table 1.  
9  
10 Induction BCG was first introduced by Morales et al. and is normally given using a six-  
11  
12 weekly regime. Results from the SWOG 8507 trial<sup>9</sup> and European Organisation for  
13  
14 Research and Treatment of Cancer (EORTC) 30911 trial<sup>27</sup>, recommend an induction  
15  
16 regimen of weekly instillations for six weeks, followed by a maintenance schedule of  
17  
18 weekly instillations for three weeks at months 3, 6, 12, 18, 24, 30, and 36 for a total of  
19  
20 27 instillations for three years. Maintenance for three years was affirmed by a  
21  
22 subsequent EORTC trial<sup>35</sup>. This regimen has now been recommended by the  
23  
24 American Urological Association (AUA) and the European Association of Urology  
25  
26 (EAU) as well as in local guidelines<sup>36-39</sup>. The EAU guidance recommends that at least  
27  
28 one year of maintenance treatment is required to gain superior outcomes over  
29  
30 Mitomycin (MMC) treatment<sup>8</sup>. The absence of an established optimal induction and  
31  
32 maintenance schedule may be as a consequence of the wide variations in regimes in  
33  
34 current use<sup>40-42</sup>. Moreover, the original and subsequent trial design irrespective of  
35  
36 minor variations have all adopted an induction and maintenance model yet report high  
37  
38 levels of attrition. Clinical practice has adopted the same model.  
39  
40  
41  
42  
43  
44  
45  
46

47 This paper presents the results of a study investigating the clinical experiences of  
48  
49 patients receiving BCG treatment, using retrospective time interval analysis from case  
50  
51 notes. This was the first phase in a larger mixed methods study exploring the reasons  
52  
53 why patients withdrew from BCG treatment early.  
54  
55  
56  
57

58 Insert Table 1  
59  
60

1  
2  
3  
4  
5 From the literature the following question emerged which the time interval analysis  
6 sought to answer: what were the patterns that have been recorded for withdrawal from  
7 treatment? and what individual factors influenced withdrawal from BCG treatment?  
8  
9  
10  
11  
12  
13

## 14 **2. Methods**

15  
16 A retrospective time interval analysis was undertaken.  
17  
18

### 19 **3.1. Population**

20  
21 The study was undertaken in a cancer centre based in a large National Health Service  
22 Hospital Trust serving a large metropolitan area in Northern England. The area had  
23 traditionally been characterised by heavy industries such as coal mining and textiles,  
24 but, latterly as chemical manufacturing. One in six of the local population are aged 65  
25 years or over <sup>43</sup>.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 This population is diverse and undergoing change. Partly in consequence of easing of  
36 European borders, allowing easier movement of working age adults seeking  
37 employment. The ethnic make-up of the white population in this area has changed,  
38 growing from 3.3% in 2001 to 7.2% in 2011. This is due to an influx of a largely Eastern  
39 European population e.g. Polish. The remainder of the population are of a black and  
40 ethnic minority population predominately of Indian sub-continent heritage. The district  
41 is the 67<sup>th</sup> out of 326 districts, most deprived districts in England, with 12.5% living in  
42 areas rated in the 10% most deprived. Life expectancy of local males is 77 years and  
43 81 years for females. Cancer incidence and mortality in this district is higher than other  
44 manufacturing towns in England <sup>43</sup>.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### 3.2. Sample

Patients aged over 18 years with a histological diagnosis of NMIBC were included in this analysis. They had a grading of grade 3 bladder cancer with one, or a combination of, the following stages: Ta; T1; or carcinoma in situ (CIS). Commencing BCG treatment within the 12 months prior to the commencement of this study and had withdrawn from treatment. Patients who had progression or recurrence of bladder cancer and were not receiving BCG treatment were excluded.

A sample of 234 sets of patient case notes (1st January 2004 to 31st December 2011), fitted the inclusion criteria, which were included in this study. This was considered representative of the population<sup>44</sup>. The characteristics of the sample are described in table 2.

Ethical approval was obtained from local research ethics committee (12/YH/0481) and the university where study was conducted. The researchers were not involved in the administration of intravesical BCG treatment or in the management of any of the healthcare professionals (HCPs) within the units where treatment was given.

### 3. Data Collection

A data extraction tool was designed and pilot tested by the researcher. Only the researcher conducted the data extraction. The clinical data relating to BCG treatment received by patients gathered also illustrated the 'natural history' of BCG treatment and identified trends concerning symptomology e.g. timing of symptom occurrence

1  
2  
3 and decisions recorded for treatment withdrawal. The tool was tested on a sample  
4 selection of case notes (n=10) and adjustments made to refine the tool.  
5  
6  
7  
8  
9

10 During the study, the NHS Trust moved towards being 'paper-light', hampering  
11 healthcare records collection of the data in three ways. Firstly, for those patients who  
12 still had paper notes, locating the notes and in many cases retrieving from storage  
13 took multiple requests and time delays. Secondly, paper notes already scanned into  
14 the electronic data management system posed different challenges. Such as delays  
15 caused by the time taken to scan documents and upload them and two the volume of  
16 screens of scanned documents per case note, as many as 500, which needed to be  
17 reviewed to extract relevant data. Thirdly, some prescription cards were held by each  
18 unit and not with the case notes and these needed to be examined separately.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

#### 33 **4. Data Analysis**

34  
35 Once extraction was completed, all data were transferred into IBM SPSS version 20  
36 for Windows. Data were then analysed using the Kaplan-Meier method. This allows  
37 estimation of withdrawal over time, even when patients remain the study for different  
38 lengths of time <sup>45</sup>. Cox regression modelling was used to interrogate withdrawal data,  
39 allowing treatment effects to be isolated from influences of other variables <sup>45,46</sup>.  
40  
41  
42  
43  
44  
45  
46  
47  
48

#### 49 **5. Results**

50  
51 There appears to be several significant factors or patterns that arise from the case-  
52 note analysis, which indicates a withdrawal rate of 90% and that the majority withdraw,  
53 107 (46%), from treatment within the first year. The most commonly recorded side  
54 effects involved a treatment related pain dimension e.g. pain, cystitis, sore genitalia.  
55  
56  
57  
58  
59  
60

1  
2  
3 Urinary side effects such as frequency and urgency were also commonly reported.  
4  
5 Age was also an important factor, as those who were 70 years or over were more likely  
6  
7 to withdraw from treatment.  
8  
9

10  
11  
12 The findings are presented in five sections: study population and characteristics;  
13  
14 patterns of withdrawal; factors influencing withdrawal; decisions for withdrawal; and  
15  
16 Likelihood of withdrawal. The term 'time to event' for this study is defined as being the  
17  
18 time taken to the event of interest namely withdrawal from BCG treatment.  
19  
20  
21

### 22 23 24 6.1. Study population and characteristics

25  
26 Most participants were aged over 70 years, 140 (61%), and the majority were male,  
27  
28 188 (80%). Only 23 (10%) of the sample population completed the full three-year  
29  
30 treatment regimen lower than the 16% identified in the South Western Oncology Group  
31  
32 (SWOG) trial <sup>9</sup>.  
33  
34  
35  
36  
37

38 Table. 2.  
39  
40  
41

### 42 6.2. Patterns of withdrawal

43  
44 The time to event analysis looked at protocol deviation by charting each instillation  
45  
46 and the timing between instillations. Thereby, looking for patterns or areas of  
47  
48 variability. These variations can be seen in Figures 1-7, which illustrate a number of  
49  
50 curves. The significance of the divergent patterns is addressed with the log rank test,  
51  
52 this showed that there was correlation with age and that the chance of an event  
53  
54 occurring e.g. having a side effect, rises with age. The data also shows that those who  
55  
56  
57  
58  
59  
60

1  
2  
3 experienced one or more side effects were more likely to withdraw from treatment  
4  
5 early, 71 (53%) withdrawing within 35 days of starting treatment.  
6  
7  
8  
9

10 Fig. 1 shows when each participant completed treatment. The largest withdrawal  
11 occurs prior to the one-year mark. From these data, 36 (15%), of patients extended  
12 treatment beyond the three-year treatment protocol. This may be due to delays in the  
13 instillations, which then offset other instillations, being given later than planned, or the  
14 possibility that the patient had been lost to follow up and then continued when found.  
15  
16  
17  
18  
19  
20  
21  
22

23  
24 Fig. 1.  
25  
26  
27

28 Figure 2 shows that by concentrating the curve to 36 months, representing three years  
29 of treatment, it shows that patients are more likely to withdraw from treatment within  
30 the first 365 days (one year). On interrogation of those 107 (46%) of patients that  
31 withdrew by 12 months, one year), of treatment a greater proportion, 39 (36%),  
32 withdrew within the first 42 days (see Figure 3).  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 Fig. 2.  
44  
45  
46

47 Fig. 3.  
48  
49  
50

### 51 6.3. Factors influencing withdrawal

52 Fig. 4 shows comparison of time to withdrawal from treatment by age. Participants  
53 aged over 70 years have a lower time to event probability than those aged 69 years  
54 or younger. Log rank statistic 17.34 ( $p=0.001$ ). Age in this population was a significant  
55  
56  
57  
58  
59  
60

1  
2  
3 factor in withdrawal from treatment. Likewise, those who experienced one or more side  
4 effect associated with BCG treatment (log rank statistic 7.27 ( $p=0.007$ )) were more  
5 likely to withdraw from treatment (See Figure 5).  
6  
7  
8  
9  
10  
11

12 Fig. 4.

13  
14 Fig. 5.

15  
16  
17  
18  
19 As contact with a clinical nurse specialist (CNS) is one of the standards recommended  
20 in cancer standards <sup>47</sup> compliance with this requirement was extracted from the case  
21 notes. Figure. 6 shows if a record of a patient receiving CNS contact information  
22 whereas Figure 7 illustrates receiving information about the treatment from a CNS.  
23  
24 From these data it appears that receipt of contact details of a CNS (log rank statistic  
25 4.46;  $p= 0.035$ ) or receiving information about the procedure and side effects (log rank  
26 statistic 23.052) ( $p<0.001$ ) was more likely to be associated with withdrawal from  
27 treatment.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Fig. 6.

41  
42  
43  
44 Fig. 7.

#### 45 46 47 48 49 6.4. Decisions for withdrawal

50  
51 The reasons recording decisions to withdraw from treatment were categorised into five  
52 broad areas: Side effects, patient/carers, hospital related, disease related, or other  
53 reasons. The largest single grouping was treatment associated side effects (see  
54 Figures 8-10). The time to event analysis revealed, what appeared to be a natural age  
55  
56  
57  
58  
59  
60

1  
2  
3 group split. Participants were grouped 69 years or younger and those aged 70 years  
4 or over. When categorised by age, there was little difference in the reasons given for  
5 withdrawing from treatment. Documented side effects appeared to be a major  
6 contributor to the decision to withdraw with two thirds, 156 (67%) of participants, with  
7 at least one side effect recorded.  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 Fig. 8.

18  
19  
20  
21 Fig. 9.

22  
23  
24  
25  
26 Fig. 10.

27  
28  
29  
30  
31 Side effects experienced are shown in Figs. 11-13. The majority of reported local  
32 symptoms were urinary including frequency of urination (n=41, 39%), haematuria (n=  
33 33, 31%), cystitis (n= 29, 28%) etc. Generalised pain which was not localised (n=22,  
34 31%) was reported as being the most common systemic side effect. Unknown  
35 reactions (where a reaction was recorded, but no details given) (n=18, 39%) and  
36 difficulty in catheterisation were the most common other side effects reported.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Fig. 11.

48  
49  
50  
51 Fig. 12.

52  
53  
54  
55  
56 Fig. 13.  
57  
58  
59  
60

## 6.5. Likelihood of withdrawal

In the Cox regression modelling that was undertaken, all variables were considered for inclusion were screened. Those which did not appear important individually or comprised categories with frequencies too low to analyse were excluded. The remaining variables were then analysed in combination to identify any emerging patterns. This method assumes that covariates are multiplicatively related to the hazard e.g. experiencing a side effects raises the likelihood of withdrawal <sup>48</sup>. Variables included were those that: had a low p-value ( $\leq 0.05$ ) at 'screening stage' indicating the likelihood the variable occurring by chance was less than 5%; were clinically important (side effects recorded as reason for patient withdrawal); or those selected through automated selection routine which the proportionality of the hazards assumption was validated. The variables that appear significant are presented in Table 3.

Table 3

## 6. Discussion

A major cause for early withdrawal was side effects, although age was associated with higher withdrawal rates. The reasons given for withdrawal from treatment were the same, or similar, in all age groups except for side effects. It was found that 31 (40%) of participants aged 69 years or younger side effects were cited as a reason for withdrawing from treatment, a higher proportion than the 44 (33%) of participants aged 70 years or older. These results are in contrast to Heiner and Terris's study, where the number of patients who experienced side effects aged 70 years or over were higher than in patients 69 years or younger respectively, 56% vs. 40% <sup>49</sup>. Although reported as significant ( $p < 0.00001$ ), the study sample was small, 58 participants, with only 22

1  
2  
3 experiencing side effects suggesting it was underpowered. The number of participants  
4 who experienced side effects were greater 156 participants in this study; with 92 (59%)  
5 aged over 70 years experiencing at least one side effect. An alternate explanation  
6 could relate the strains and/or doses of BCG administered. In the absence of  
7 consistent practice regarding optimum strain or dose <sup>30-32</sup>, this inconsistency may  
8 explain varying levels of withdrawal. Similarly, differences in number and severity of  
9 side effects experienced may strain or dose dependent. Within this analysis all patients  
10 received the same strain of BCG.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Some suggest that interstitial BCG treatment needs to be administered cautiously in  
25 patients 70 years or older and only after careful consideration due to poor reserves  
26 that these patients may have to cope with the treatment <sup>50</sup>. This is predicated on the  
27 basis that side effects from BCG treatment would not be as well tolerated in elderly  
28 patients and may become problematic in terms of adherence. This pattern was seen  
29 in this study population. Whether this was a consequence of poor toleration or the  
30 treatment burden was in excess of physical reserves and/or co-morbidity was not  
31 assessed.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 The analysis supports the given view that side effects experienced affects attrition.  
46 Patients who are well prepared about what to expect, such as those involved in clinical  
47 trials, may be better prepared when encountering side effects; in effect they cope by  
48 normalising the abnormal. The results of this study suggest that those patients who  
49 are given more information, were more likely to withdraw.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 A surprising feature of this study and should be treated cautiously, was contact with a  
4  
5 CNS may not contribute to keeping patients on treatment for longer. The reasons for  
6  
7 this finding are unknown but warrants further investigation, particularly, as in other  
8  
9 cancer site specific studies CNS input seems to improve outcomes <sup>51</sup>. However, this  
10  
11 could be related to poor record keeping, in that those case records where details of  
12  
13 the CNS were provided, patients were more likely to withdraw from treatment early,  
14  
15 than those whose records showed they only received written information.  
16  
17  
18  
19  
20

21  
22 The time to event analysis of withdraw from treatment revealed a natural age group  
23  
24 split with patients 69 years and under more likely to tolerate and continue to receive  
25  
26 BCG for nine months longer than those aged 70 years and above. Further, 63% of the  
27  
28 population aged above 70 years old in this study were more likely to withdraw reasons  
29  
30 for attrition were similar. Not only was there a correlation between age and the chance  
31  
32 of the event occurring, but the modelling highlighted that the percentage chance of the  
33  
34 event occurring rises with age.  
35  
36  
37  
38  
39

40 During data extraction three patient records documented the rationale for treatment  
41  
42 cessation as 'advanced age'. This does question whether an adequate assessment  
43  
44 was completed prior to treatment. The higher number of participants aged 70 years or  
45  
46 greater in the study probably reflects the local population, with increasing life  
47  
48 expectancy and effects of exposure to dye, printing, iron, industrial painting, gas and  
49  
50 tar industries during employment only presenting long after exposure <sup>8</sup>. This  
51  
52 generation may not have benefitted from the impact of health and safety legislation in  
53  
54 the work place or recent anti-smoking campaigns <sup>52</sup>.  
55  
56  
57  
58  
59  
60

1  
2  
3 There is clear evidence of side effects associated with BCG use <sup>9,26,27</sup>. Reportedly  
4 between 20% and 80% of patients experience mild to severe local or systematic, side  
5 effects <sup>53–55</sup>. The reported studies do not detail the effect that side effects have on the  
6 patient.  
7  
8  
9  
10  
11  
12

13  
14 This study discovered that 67% of patients who experienced one or more side effect,  
15 such as cystitis or incontinence, were more likely to withdraw early. The analysis  
16 showed that 55% of participants withdrew within the first year. Of these, 39% withdrew  
17 within 42 days of treatment commencing, hence failing to complete the induction  
18 phase of the treatment (the initial six instillations). Data regarding subsequent  
19 treatment(s) if any or long terms outcomes was not extracted and therefore any  
20 assumptions about whether patients were being put at risk of recurrence through early  
21 withdrawal are unknown. That said poor selection for BCG may have delayed  
22 alternative interventions.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Nearly half of the of participants (45%) reported at least one local side effect e.g.  
39 urinary frequency; with 30% reporting at least one systemic side effect; and 20%  
40 reporting at least one other side effect or treatment related complication e.g. difficulty  
41 in catheterisation. The most common local side effect reported was cystitis and  
42 according to Lamm et al. experienced in around 80% receiving BCG <sup>53</sup>. In contrast, in  
43 this study, cystitis was recorded in only 28% of cases (Fig. 11). The most commonly  
44 recorded local side effect in was urinary frequency in 39% of cases. A possible reason  
45 for differences in symptom incidence may relate to how side effects were reported  
46 and/or recorded in case notes. Cystitis involves both frequency and pain, or a burning  
47 sensation, when urinating <sup>56</sup>. As the instillation of BCG is largely a nurse led service,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 in that the CNS counsels the patient, instills the BCG, records in the case notes and  
4 discharges the patient from the unit. They remain the main contact for the patient when  
5 they go home, therefore, this impacts onto any findings. The CNS may have recorded  
6 these side effects separately, or one in preference to both, or interpreted the  
7 symptoms and given a different descriptor thereby skewing the actual number of  
8 participants who did have the side effect of cystitis.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 It is unclear in the literature when side effects occur. Some authors indicate that side  
20 effects can occur during the induction phase of the treatment, however they do not  
21 suggest that there is a cumulative effect from the BCG instillations when the symptoms  
22 appear during maintenance <sup>49,57-59</sup>. In this study there were 53% reports of side effects  
23 experienced within 35 days of starting treatment indeed for some these started within  
24 the first week of treatment commencing.  
25  
26  
27  
28  
29  
30  
31  
32  
33

34  
35 A limitation of all studies interrogating clinically available data, is the quality of the  
36 original record keeping and accuracy of data extraction. As this study used paper-  
37 based notes (patient records and prescription charts) this may have introduced greater  
38 levels of inaccuracy as clinician preference and style may influence what is recorded.  
39 Unlike electronic records which force data entry arguably increasing reliability <sup>60</sup>.  
40 Although some suggest the problem of data accuracy has more to do with why it is  
41 collected namely research versus clinical purposes. The introduction of electronic  
42 health records may have increased the tendency for bad data recording rather than  
43 greater accuracy <sup>61</sup>.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 7. Conclusions

From this retrospective time interval analysis of clinical data withdrawal rates from BCG treatment were higher than those published in the literature. The patterns that emerged associated with age and experience of side effects appeared to significantly affect the decision making regarding early withdrawal from treatment. The majority of attrition appears to occur within the first year of treatment, and indeed a sizable group prior to completing induction. Possibly the most surprising finding was that clinical nurse contact and information provision seemed to exacerbate early withdrawal. This may be an anomaly associated with a real-world nurse led service design. What is clear is that further research is required to fully understand these results, but they contribute real world insight into the experience of a 'gold standard' treatment.

## References

1. Cancer research UK. Bladder cancer statistics | Cancer Research UK.
2. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: The epidemiology of bladder cancer. *Nat Clin Pract Urol*. 2006;3(6):327-340.
3. Office for National Statistics. 170 years of industrial change across England and Wales. <http://www.ons.gov.uk/ons/rel/census/2011-census-analysis/170-years-of-industry/170-years-of-industrial-changeponent.html>. Published 2013. Accessed August 30, 2014.
4. Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol*. 2013;63(2):234-241. doi:10.1016/j.eururo.2012.07.033
5. Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. *Eur Urol*. 2014;66(1):59-73. doi:10.1016/j.eururo.2013.10.001
6. Freedman ND. Association Between Smoking and Risk of Bladder Cancer Among Men and Women. *JAMA*. 2011;306(7):737. doi:10.1001/jama.2011.1142
7. van Osch FH, Jochems SH, van Schooten F-J, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. *Int J Epidemiol*. 2016;45(3):857-870. doi:10.1093/ije/dyw044
8. Babjuk M, Burger M, Compérat E, et al. Non-muscle-invasive Bladder Cancer. <http://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/>. Published 2017. Accessed April 9, 2018.

- 1  
2  
3 9. Lamm D, Blumenstein B, Crissman J, et al. Maintenance bacillus Calmette-  
4  
5 Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional  
6  
7 cell carcinoma of the bladder: A randomized Southwest Oncology Group  
8  
9 Study. *J Urol.* 2000;163(4):1124-1129.
- 10  
11  
12 10. Crispen R. History of BCG and its substrains. *Prog Clin Biol Res.* 1989;310:35-  
13  
14 50.
- 15  
16  
17 11. Huang T. Management of complications of bacillus Calmette-Guerin  
18  
19 immunotherapy in the treatment of bladder cancer. *Ann Pharmacother.*  
20  
21 2000;34(4):529-532.
- 22  
23  
24 12. Pearl R. Cancer and tuberculosis. *Am J Hyg.* 1929;9(1):97-159.
- 25  
26  
27 13. Mathe G, Amiel J, Schwarzenberg L, et al. Active immunotherapy for acute  
28  
29 lymphoblastic leukaemia. *Lancet.* 1969;1(7597):697-699.
- 30  
31  
32 14. Morton D, Eilber F, Malmgren R, Wood W. Immunological factors which  
33  
34 influence response to immunotherapy in malignant melanoma. *Surgery.*  
35  
36 1970;68(1):158-163.
- 37  
38  
39 15. Zbar B, Bernstein I, Bartlett G, Hanna M, Rapp H. Immunotherapy of cancer:  
40  
41 Regression of intradermal tumors and prevention of growth of lymph node  
42  
43 metastases after intralesional injection of living mycobacterium bovis. *J Natl*  
44  
45 *Cancer Inst.* 1972;49(1):119-130.
- 46  
47  
48 16. Coe J, Feldman J. Extracutaneous delayed hypersensitivity, particularly in the  
49  
50 guinea-pig bladder. *Immunology.* 1966;10(2):127-136.
- 51  
52  
53 17. Morales A, Eidinger D, Bruce A. Intracavitary Bacillus Calmette-Guerin in the  
54  
55 treatment of superficial bladder tumors. *J Urol.* 1976;116(2):180-183.
- 56  
57  
58 18. Lamm D. Bacillus Calmette-Guerin immunotherapy for bladder cancer. *J Urol.*  
59  
60 1985;134(1):40-47.

19. Mori K, Lamm D, Crawford E. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: A south-west oncology group study. *Urol Int.* 1986;41(4):254-259.
20. Herr H, Pinsky C, Whitmore W, Oettgen H, Melamed M. Effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. *Cancer.* 1983;51(7):1323-1326.
21. Herr H, Pinsky C, Whitmore W, Sogani P, Oettgen H, Melamed M. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors. *Urology.* 1985;25(2):119-123.
22. Melekos M, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G, Dauaher H. Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: Results of a controlled prospective trial with modified treatment schedule. *J Urol.* 1993;149(4):744-748.
23. Krege S, Giani G, Meyer R, Otto T, Rübber H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. *Participating Clinics. J Urol.* 1996;156(3):962-966.
24. Lamm D. Long-term results of intravesical therapy for superficial bladder cancer. *Urol Clin North Am.* 1992;19(3):573-580.
25. Bohle A, Jocham D, Bock P. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. *J Urol.* 2003;169(1):90-95.
26. Hinotsu S, Akaza H, Naito S, et al. Maintenance therapy with bacillus calmette-guerin connaught strain clearly prolongs recurrence-free survival following

- 1  
2  
3 transurethral resection of bladder tumour for non-muscle-invasive bladder  
4  
5 cancer. *BJU Int.* 2010;108(2):187-195.  
6  
7  
8 27. Sylvester R, Brausi M, Kirkels W, et al. Long-term efficacy results of EORTC  
9  
10 genito-urinary group randomized phase 3 study 30911 comparing intravesical  
11  
12 instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-  
13  
14 Guérin plus isoniazid in patients with intermediate- and high-risk. *Eur Urol.*  
15  
16 2010;57(5):766-773.  
17  
18  
19 28. Sylvester R, van der Meijden A, Lamm D. Intravesical bacillus Calmette-Guerin  
20  
21 reduces the risk of progression in patients with superficial bladder cancer: a  
22  
23 meta-analysis of the published results of randomized clinical trials. *J Urol.*  
24  
25 2002;168:1964-1970.  
26  
27  
28 29. Shelley M, Kynaston H, Court J, et al. A systematic review of intravesical  
29  
30 bacillus Calmette-Guérin plus transurethral resection vs transurethral resection  
31  
32 alone in Ta and T1 bladder cancer. *BJU Int.* 2001;88(3):209-216.  
33  
34  
35 30. Shelley M, Court J, Kynaston H, Wilt T, Fish R, Mason M. Intravesical Bacillus  
36  
37 Calmette-Guérin in Ta and T1 bladder cancer (Review). *Cochrane Libr.*  
38  
39 2010;(3).  
40  
41  
42 31. Fonseca F, Bachega W, Zequi S, et al. Treatment of patients with superficial  
43  
44 bladder cancer stratified by risk groups treated with lyophilized Moreau-Rio de  
45  
46 Janeiro BCG strain. *Int Brazilian J Urol.* 2002;28(5):426-435.  
47  
48  
49 32. Hudson M, Ratliff T, Gillen D, Haaff E, Dresner S, Catalona W. Single course  
50  
51 versus maintenance bacillus Calmette-Guerin therapy for superficial bladder  
52  
53 tumors: a prospective, randomized trial. *J Urol.* 1987;162(2):339-342.  
54  
55  
56 33. Kamat AM, Flaig TW, Grossman HB, et al. Expert consensus document:  
57  
58 Consensus statement on best practice management regarding the use of  
59  
60



- 1  
2  
3 intravesical immunotherapy with BCG for bladder cancer. *Nat Rev Urol*.  
4  
5 2015;12(4):1-11.  
6  
7  
8 34. Rentsch C, Birkhäuser F, Biot C, et al. Bacillus Calmette-Guérin strain  
9  
10 differences have an impact on clinical outcome in bladder cancer  
11  
12 immunotherapy. *Eur Urol*. 2014;66(4):677-688.  
13  
14  
15 35. Oddens J, Brausi M, Sylvester R, et al. Side effects of bacillus calmette-guérin  
16  
17 (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary  
18  
19 carcinoma of the bladder: Results of the EORTC genito-urinary cancers group  
20  
21 randomised phase 3 study comparing one-third dose with full dose an. *Eur*  
22  
23 *Urol*. 2014;65(1):69-76. <http://www.ncbi.nlm.nih.gov/pubmed/23141049>.  
24  
25 Accessed October 24, 2016.  
26  
27  
28 36. Hall M, Chang S, Dalbagni G, et al. Guideline for the management of  
29  
30 nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. *J*  
31  
32 *Urol*. 2007;178(6):2314-2330.  
33  
34  
35 37. Babjuk M, Böhle A, Burger M, et al. *Guidelines on Non-Muscle-Invasive*  
36  
37 *Bladder Cancer (Ta, T1 and CIS)*. European Association of Urology; 2014.  
38  
39  
40 38. National Comprehensive Cancer Network. Clinical practice guidelines in  
41  
42 oncology: bladder cancer including upper tract tumors and urothelial  
43  
44 carcinoma of the prostate. 2012.  
45  
46  
47 39. Paul A, Carey B, Cross B, Rock C, Singh P. Guidelines for the investigation  
48  
49 and treatment of bladder, renal and prostate cancers. Yorkshire Cancer  
50  
51 Network. [http://www.yorkshire-cancer-net.org.uk/html/downloads/ycn-urology-](http://www.yorkshire-cancer-net.org.uk/html/downloads/ycn-urology-bladder-renal-prostate-guidelines-sept2012-v2.0.pdf)  
52  
53 [bladder-renal-prostate-guidelines-sept2012-v2.0.pdf](http://www.yorkshire-cancer-net.org.uk/html/downloads/ycn-urology-bladder-renal-prostate-guidelines-sept2012-v2.0.pdf). Published 2012.  
54  
55 Accessed October 16, 2012.  
56  
57  
58 40. Zlotta A, Van Vooren J, Huygen K, et al. *What Is the Optimal Regimen for*  
59  
60

- 1  
2  
3 *BCG Intravesical Therapy? Are Six Weekly Instillations Necessary? Vol 37.;*  
4  
5 2000.  
6  
7  
8 41. Kitamura H, Tsukamoto T. Immunotherapy for urothelial carcinoma: Current  
9 status and perspectives. *Cancers (Basel)*. 2011;3(3):3055-3072.  
10  
11  
12 42. Lockyer C, Gillatt D. BCG immunotherapy for superficial bladder cancer. *J R*  
13 *Soc Med*. 2001;94(3):119-123.  
14  
15  
16 43. Wakefield Together Partnership. *Our Wakefield: The State of District Report*  
17 *Winter 2012 Update*. Wakefield: Wakefield Together Partnership; 2012.  
18  
19  
20 44. Patel M, Doku V, Tennakoon L. Challenges in recruitment of research  
21 participants. *Adv Psychiatr Treat*. 2003;9(3):229-238.  
22  
23  
24 45. Buchan I. Statistical Help. Statsdirect.  
25  
26 [http://www.statsdirect.com/help/Default.htm#contents.htm?TocPath=\\_\\_\\_\\_\\_1](http://www.statsdirect.com/help/Default.htm#contents.htm?TocPath=_____1).  
27  
28 Published 2016. Accessed July 17, 2016.  
29  
30  
31 46. Walters S. *What Is a Cox Model?* 2nd ed. Hayward Medical Communications;  
32 2009.  
33  
34  
35 47. National Institute for Clinical Excellence. *Guidance on Cancer Services:*  
36 *Improving Outcomes in Urological Cancers – The Manual*. London: National  
37 Institute for Clinical Excellence; 2002.  
38  
39  
40 48. Breslow N. Analysis of Survival Data under the Proportional Hazards Model.  
41 *Int Stat Rev / Rev Int Stat*. 1975;43(1):45-57.  
42  
43  
44 49. Heiner J, Terris M. Effect of advanced age on the development of  
45 complications from intravesical bacillus Calmette-Guérin therapy. *Urol Oncol*.  
46 2008;26(2):137-140.  
47  
48  
49 50. Shariat S, Milowsky M, Droller M. Bladder cancer in the elderly. *Urol Oncol*.  
50 2009;27(6):653-667.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 51. Tod AM, Redman J, McDonnell A, Borthwick D, White J. Lung cancer  
4 treatment rates and the role of the lung cancer nurse specialist: a qualitative  
5 study. *BMJ Open*. 2015;5(12):e008587. doi:10.1136/bmjopen-2015-008587  
6  
7  
8  
9
- 10 52. ASH: Action on Smoking and Health. <http://www.ash.org.uk/>. Published 2016.  
11 Accessed July 17, 2016.  
12  
13
- 14 53. Lamm D, Persad R, Colombel M, Brausi M. Maintenance bacillus Calmette-  
15 Guérin: The standard of care for the prophylaxis and management of  
16 intermediate- and high-risk non-muscle-invasive bladder cancer. *Eur Urol*  
17 *Suppl*. 2010;9(9):715-734.  
18  
19  
20  
21  
22
- 23 54. van der Meijden A, Sylvester R, Oosterlinck W, Hoeltl W, Bono A.  
24 Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not  
25 associated with increased toxicity: Results from a european organisation for  
26 research and treatment of cancer genito-urinary group phase III trial. *Eur Urol*.  
27 2003;44(4):429-434.  
28  
29  
30  
31  
32  
33
- 34 55. Bohle A, Balck F, Wietersheim J, Jocham D. The quality of life during  
35 intravesical bacillus Calmette-Guerin therapy. *J Urol*. 1996;155:1221-1226.  
36  
37  
38  
39
- 40 56. Bruschi J, Bavaro M, Cunha B, Tessler JM. Urinary Tract Infection (UTI) and  
41 Cystitis (Bladder Infection) in Females: Practice Essentials, Background,  
42 Pathophysiology. Medscape. [https://emedicine.medscape.com/article/233101-](https://emedicine.medscape.com/article/233101-overview#showall)  
43 [overview#showall](https://emedicine.medscape.com/article/233101-overview#showall). Published 2017. Accessed April 23, 2018.  
44  
45  
46  
47  
48
- 49 57. Orihuela E, Herr H, Pinsky C, Whitmore W. Toxicity of intravesical BCG and its  
50 management in patients with superficial bladder tumors. *Cancer*.  
51 1987;60(3):326-333.  
52  
53  
54
- 55 58. Berry D, Blumenstein B, Magyary D, Lamm D, Crawford E. Local toxicity  
56 patterns associated with intravesical bacillus Calmette-Guérin: A Southwest  
57  
58  
59  
60

- 1  
2  
3 Oncology Group Study. *Int J Urol*. 1996;3(2):98-100.  
4  
5  
6 59. Mack D, Frick J. Quality of life in patients undergoing bacille Calmette-Guérin  
7  
8 therapy for superficial bladder cancer. *Br J Urol*. 1996;78(3):369-371.  
9  
10  
11 60. Kuhn T, Basch P, Barr M, et al. Clinical documentation in the 21st century:  
12  
13 Executive summary of a policy position paper from the American College of  
14  
15 Physicians. *Ann Intern Med*. 2015;162(4):301-303. doi:10.7326/M14-2128  
16  
17 61. Weiskopf N, Weng C. Methods and dimensions of electronic health record  
18  
19 data quality assessment: Enabling reuse for clinical research. *J Am Med*  
20  
21 *Informatics Assoc*. 2013;20(1):144-151. doi:10.1136/amiajnl-2011-000681  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Fig. 1: Early withdrawal or course completion overall view




Fig. 2: Early withdrawal or completed 36 months (three years) of treatment




Fig. 3: Early withdrawal or completed 12 months (one year) of treatment




Fig. 4: Treatment withdrawal by age group




Fig. 5: Early withdrawal through side effects




Fig. 6: CNS contact details given to a patient




Fig. 7: Written information given to a patient




Fig. 8: Reasons given for withdrawal






Fig. 9: Comparison of withdrawal reasons by age




Fig. 10: Recorded number of side effects from case notes




Fig. 11: Reported local side effects




Fig. 12: Reported systemic side effects





Fig. 13: Reported 'other' side effects



Peer Review

Table 1: Studies showing BCG dose, strain and treatment regime

Study	Dose / Strain	Induction Regime	Maintenance Regime	Percutaneous BCG
Morales et al. (1976)	120mg / Armand Frappier	Weekly for 6 weeks	No	Yes
Herr et al. (1983)	120mg / Armand Frappier	Weekly for 6 weeks	No	Yes
Badalament et al. (1987)	120mg / Armand Frappier	Weekly for 6 weeks	Monthly for 2 years	No
Hudson et al. (1987)	120mg / Pasteur	No	1 instillation every 3 months for 2 years	No
Agrawal et al. (2007)	40,80,120mg / Modified Danish 1331	Weekly for 6 weeks	Monthly for 1 year	No
Ali-el-dein et al. (1999)	150mg / Strain not given	Weekly for 6 weeks	Monthly for 10 months	No
Andius & Holmang (2004)	Dose not stated / Modified Danish 1331 & TICE	Weekly for 6 weeks	Monthly for 2 years	No
Orihuela et al. (1987)	120mg / Pasteur	Weekly for 6 weeks	No	Yes
Lamm et al. (1995)	50 mg / TICE	Weekly for 6 weeks	Monthly for 1 year	No
Bohle et al. (1996)	150mg / Connaught	Weekly for 6 weeks	No	No
Krege et al. (1996)	120mg / Connaught	Weekly for 6 weeks	Monthly for 4 months	No
Taniguchi et al. (1999)	80mg / Tokyo 172	Weekly for 6 weeks	No	No
Witjes et al. (1996)	5x10 <sup>8</sup> / TICE & RIVM	Weekly for 6 weeks	No	No
Witjes et al. (1998)	40mg of Mitomycin C then BCG	Weekly for 6 weeks	No	No
Lamm et al. (2000)	81mg / Connaught	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12, 18, 24, 30 and 36	Yes
Saint et al. (2001)	81mg / Connaught	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12, 18, 24, 30 and 36	No
van der Meijden et al. (2001)	5x10 <sup>8</sup> / TICE	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12, 18, 24, 30 and 36	No

Fonseca et al. (2002)	40mg / Moreau-Rio de Janeiro	6 instillations – not clear over what time period	6 instillations each 15 days	No
van der Meijden et al. (2003)	5x10 <sup>8</sup> / TICE	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12, 18, 24, 30 and 36	No
De Reijke et al. (2005)	81mg / Connaught	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12, 18, 24, 30 and 36	No
Gunlusoy et al. (2005)	120mg / Pasteur	Weekly for 6 weeks	No	No
Decobert et al. (2008)	120mg / Pacis Shire	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12, 18, 24, 30 and 36	No
Jarvinen et al. (2009)	75mg / Pasteur	Weekly for 5 weeks	Monthly for 2 years	No
Duchek et al. (2010)	Dose not stated / TICE	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12, 18, 24, 30 and 36	No
Hinotsu et al. (2010)	81mg / Connaught	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12 and 18	No
Sylvester et al. (2010)	5x10 <sup>8</sup> / TICE	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12, 18, 24, 30 and 36	No
Oddens et al. (2014)	5x10 <sup>8</sup> / TICE	Weekly for 6 weeks	Weekly for 3 weeks at months 3, 6, 12, 18, 24, 30 and 36; or	No

			Weekly for 3 weeks at months 3, 6 and 12	
Rentsch et al. (2014)	6.6–19.2 108 CFU / Connaught 2–8 108 CFU / Tice	Weekly for 6 weeks	No	No

For Peer Review

Table 2: The age distribution and gender of the population

Characteristic	n	%
<b>Age (years)</b>		
<59	28	(12)
60-69	66	(28)
70-79	111	(48)
>80	29	(13)
Mean age	71	
Standard deviation	8.54	
<b>Gender</b>		
Male	188	(80)
Female	46	(20)
<b>Course Complete</b>		
Yes	23	(10)
No	211	(90)

Table 3: Cox regression model parameters

Variable	p - value	Hazard Ratio (HR)	95.0% CI for HR	
			Lower	Upper
<b>Age</b>				
>80 (reference)				
<59	0.007	0.427	0.231	0.789
60-69	0.018	0.558	0.345	0.903
70-79	0.241	0.765	0.490	1.197
<b>Patients withdrawn due to:</b>				
No side effects or side effects (reference)				
Side effects or side effects	<0.001	5.443	3.481	8.510
No patient or carer decisions (reference)				
Patient or carer decisions	0.002	2.379	1.368	4.134
No hospital events (reference)				
Hospital events	<0.001	2.898	1.736	4.837
No miscellaneous reasons (reference)				
Miscellaneous reasons	<0.001	7.057	4.308	11.56 <sub>1</sub>
<b>Patients who received:</b>				
No information (reference)				
Information	<0.001	1.857	1.322	2.610
<b>Patients who experienced:</b>				
No local side effects (reference)				
Local side effects	0.026	0.695	0.505	0.958